Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib

被引:66
作者
Ozenne, Violaine [1 ]
Paradis, Valerie [2 ]
Pernot, Simon [1 ]
Castelnau, Corinne [1 ]
Vullierme, Marie-Pierre [3 ]
Bouattour, Mohamed [1 ,4 ]
Valla, Dominique [1 ]
Farges, Olivier [5 ]
Degos, Francoise [1 ]
机构
[1] Hop Beaujon, AP HP, Dept Hepatol, F-92110 Clichy, France
[2] Hop Beaujon, AP HP, Dept Pathol, F-92110 Clichy, France
[3] Hop Beaujon, AP HP, Dept Radiol, F-92110 Clichy, France
[4] Hop Beaujon, AP HP, Dept Oncol, F-92110 Clichy, France
[5] Hop Beaujon, AP HP, Dept HepatoBiliary Surg, F-92110 Clichy, France
关键词
hepatocellular carcinoma; prognostic markers; side-effects; sorafenib; tolerance; III SHARP TRIAL; LIVER-CIRRHOSIS; CYTOKERATIN-19; EXPRESSION; BIOMARKERS; CANCER; SAFETY; STAGE;
D O I
10.1097/MEG.0b013e3283386053
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Sorafenib is the standard treatment for patients with an advanced stage of hepatocellular carcinoma (HCC). The aims of this study were (i) to evaluate the tolerance and survival of sorafenib-treated patients, in a nonselected population, especially in Child-Pugh B patients; and (ii) to identify potential prognostic factors of survival. Patients and methods From April 2007 to December 2008, 50 patients received sorafenib for advanced HCC. Seventeen (34%) were Child-Pugh B patients. We recorded adverse events and the duration of treatment and survival. For 34 patients with histopathologically proven HCC, immunophenotypical analysis was carried out using antibodies against cluster differentiation 34, vascular endothelial growth factor, phosphorylated ERK, cytokeratin 19, and phosphorylated stat3. Results Patients with Child-Pugh B cirrhosis had a more advanced stage of the disease compared with Child-Pugh A patients. The occurrence of adverse events was similar in Child-Pugh A and Child-Pugh B patients. Duration of treatment until discontinuation for bad tolerance was lower in Child-Pugh B patients (1.8 vs. 5 months, P = 0.02). Survival of Child-Pugh A patients was higher compared with Child-Pugh B patients (8.9 vs. 2 months, P = 0.004). Barcelona Clinic Liver Cancer stage, Eastern Cooperative Oncology Group Performance Status, portal vein impairment, extra-hepatic spread, and alpha-foetoprotein were also prognostic factors. In multivariate analysis, the sole factor associated with survival was the Barcelona Clinic Liver Cancer stage. None of the immunohistological markers used was associated with tolerance and survival. Conclusion Occurrence of adverse events is similar in Child-Pugh A and Child-Pugh B patients. Nevertheless, the survival of Child-Pugh B patients is very low. Whether liver function or tumor spread is responsible for mortality is unclear. Opportunity of treatment for Child-Pugh B patients is questionable. The immunophenotype of tumoral tissue was not predictive of survival. Eur J Gastroenterol Hepatol 22: 1106-1110 (C) 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.
引用
收藏
页码:1106 / 1110
页数:5
相关论文
共 19 条
[1]   Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[2]   Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].
Cheng, Ann-Lii ;
Kang, Yoon-Koo ;
Chen, Zhendong ;
Tsao, Chao-Jung ;
Qin, Shukui ;
Kim, Jun Suk ;
Luo, Rongcheng ;
Feng, Jifeng ;
Ye, Shenglong ;
Yang, Tsai-Sheng ;
Xu, Jianming ;
Sun, Yan ;
Liang, Houjie ;
Liu, Jiwei ;
Wang, Jiejun ;
Tak, Won Young ;
Pan, Hongming ;
Burock, Karin ;
Zou, Jessie ;
Voliotis, Dimitris ;
Guan, Zhongzhen .
LANCET ONCOLOGY, 2009, 10 (01) :25-34
[3]   From proteomic analysis to clinical significance - Overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis [J].
Ding, SJ ;
Li, Y ;
Tan, YX ;
Jiang, MR ;
Tian, B ;
Liu, YK ;
Shao, XX ;
Ye, SL ;
Wu, JR ;
Zeng, R ;
Wang, HY ;
Tang, ZY ;
Xia, QC .
MOLECULAR & CELLULAR PROTEOMICS, 2004, 3 (01) :73-81
[4]   The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin [J].
Durnez, A. ;
Verslype, C. ;
Nevens, F. ;
Fevery, J. ;
Aerts, R. ;
Pirenne, J. ;
Lesaffre, E. ;
Libbrecht, L. ;
Desmet, V. ;
Roskams, T. .
HISTOPATHOLOGY, 2006, 49 (02) :138-151
[5]   Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis [J].
El-Serag, Hashem B. ;
Rudolph, Lenhard .
GASTROENTEROLOGY, 2007, 132 (07) :2557-2576
[6]   Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma [J].
Hoshida, Yujin ;
Villanueva, Augusto ;
Kobayashi, Masahiro ;
Peix, Judit ;
Chiang, Derek Y. ;
Camargo, Amy ;
Gupta, Supriya ;
Moore, Jamie ;
Wrobel, Matthew J. ;
Lerner, Jim ;
Reich, Michael ;
Chan, Jennifer A. ;
Glickman, Jonathan N. ;
Ikeda, Kenji ;
Hashimoto, Masaji ;
Watanabe, Goro ;
Daidone, Maria G. ;
Roayaie, Sasan ;
Schwartz, Myron ;
Thung, Swan ;
Salvesen, Helga B. ;
Gabriel, Stacey ;
Mazzaferro, Vincenzo ;
Bruix, Jordi ;
Friedman, Scott L. ;
Kumada, Hiromitsu ;
Llovet, Josep M. ;
Golub, Todd R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (19) :1995-2004
[7]   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].
Hurwitz, H ;
Fehrenbacher, L ;
Novotny, W ;
Cartwright, T ;
Hainsworth, J ;
Heim, W ;
Berlin, J ;
Baron, A ;
Griffing, S ;
Holmgren, E ;
Ferrara, N ;
Fyfe, G ;
Rogers, B ;
Ross, R ;
Kabbinavar, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342
[8]   PLASMA BIOMARKERS AS PREDICTORS OF OUTCOME IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: RESULTS FROM THE RANDOMIZED PHASE III SHARP TRIAL [J].
Llovet, J. ;
Pena, C. ;
Shan, M. ;
Lathia, C. ;
Bruix, J. .
JOURNAL OF HEPATOLOGY, 2009, 50 :S385-S385
[9]   Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival [J].
Llovet, JM ;
Bruix, J .
HEPATOLOGY, 2003, 37 (02) :429-442
[10]  
Llovet J, 2008, HEPATOLOGY, V48, p372A